Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foretinib in Papillary Renal-Cell Carcinoma
NCT00726323Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of foretinib in papillary renal cell carcinoma (PRCC) (2 arms), sponsored by GSK. Primary endpoint: Overall Response Rate at 4 years. Started Jun 2006; status: completed.
02
Drugs
foretinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT00726323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726323.